Breaking News

Tweet TWEET

Echo Therapeutics to Present at Biotech Showcase 2013 in San Francisco

    Echo Therapeutics to Present at Biotech Showcase 2013 in San Francisco

PR Newswire

PHILADELPHIA, Dec. 27, 2012

PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo
Therapeutics, will present at the Biotech Showcase 2013 Conference.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Dr. Mooney will make a corporate presentation to prospective corporate
partners and investors on Monday, January 7 at 2:45 PM PST. The Company's
presentation will be delivered at the Parc 55 Wyndham in San Francisco.

About Biotech Showcase™

Biotech Showcase is an investor and partnering conference devoted to providing
private and public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and pharmaceutical
executives in one place during the course of one of the industry's largest
annual healthcare investor conferences. Investors and biopharmaceutical
executives from around the world gather in San Francisco during this critical
week that is widely viewed as setting the tone for the coming year. Now in
its fifth year, this rapidly growing conference features multiple tracks of
presenting companies, plenary sessions, workshops, networking, and an
opportunity to schedule one-to-one meetings. Biotech Showcase is produced by
Demy Colton Life Science Advisors and EBD Group. Both organizations have a
long history of producing high quality programs that support the biotechnology
and broader life sciences industry.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony tCGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony tCGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking
statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com 

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx



SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com
 
Press spacebar to pause and continue. Press esc to stop.